Department of Surgery, University of Melbourne, Austin, and Repatriation Medical Centre, Melbourne, Victoria 3084, Australia
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Precursor forms of peptide
hormones may be biologically active with effects distinct from the
mature end product. Nonamidated progastrin-derived peptides stimulate
growth of colonic epithelium and are elevated in the circulation of
patients with colorectal carcinomas, whereas the amidated end product
is the major regulator of gastric acidity. Using region-specific
radioimmunoassays, we here compared the in vitro and in vivo metabolism
of recombinant human progastrin-(6-80) and two other
nonamidated gastrins, gastrin-17-Gly and
Tyr70-progastrin-(71-80). Although
progastrin-(6-80) was very stable in vitro, both
progastrin-(6-80) and gastrin-17-Gly were degraded in
vivo. The in vivo data were best fitted by a double-exponential decay
curve, and the half-lives for progastrin-(6-80)
(t1/2 = 5.1 ± 1.1, t1/2
= 42 ± 11 min) were
significantly (P < 0.05) longer than for
gastrin-17-Gly (t1/2
= 2.2 ± 0.6, t1/2
= 13 ± 1 min).
Tyr70-progastrin-(71-80) was degraded
more rapidly. Comparison with amidated gastrins suggests that peptide
length, rather than sequence, is the critical determinant of clearance.
Progastrin has the clearance characteristics to be considered a
circulating hormone.
amidation; prohormone; processing
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
PEPTIDE HORMONES ARE
PROCESSED from large precursors through a series of intermediates
to a final end product that is often amidated (11).
Gastrin is synthesized as a large precursor of 101 amino acids, which,
after cleavage of the signal peptide, yields progastrin (80 amino
acids). Subsequent processing results in the generation of
glycine-extended gastrins (gastrin-34-Gly and gastrin-17-Gly), with the
final step being amidation to amidated gastrins (gastrin-34 amide and
gastrin-17 amide) (Fig. 1) (9, 36). There is increasing evidence that the precursor forms and the end product have distinct biological activities mediated by different receptors (3, 31). Gastrin amide is the major
hormonal regulator of gastric acid secretion (13, 36) and
acts as a mitogen for normal gastric epithelium and some gastric cancer cell lines in vitro and in vivo (9, 17, 20). The
cholecystokinin (CCK)-B/gastrin receptor, which mediates the
acid-stimulatory and proliferative effects of gastrin amide is a member
of a family of receptors with seven transmembrane segments (21,
39). In contrast, the precursor forms and intermediates such as
gastrin-17-Gly and progastrin have little direct effect on gastric
acidity (8, 26) but stimulate the proliferation of
colorectal carcinomas (both in vitro and in vivo) and normal colon
(1, 3, 20, 33). The receptors mediating the effects of
gastrin-17-Gly and progastrin have not been defined.
|
Nonamidated forms of gastrin are present in increased concentrations in the circulation of patients with colorectal carcinoma relative to normal controls (6, 32). Progastrin and gastrin-Gly have also been detected in colorectal tumors (6, 19, 23, 34), but it is still not established whether nonamidated gastrins function as autocrine regulators of tumor development or whether there is also increased secretion from the normal antral source of gastrin (3). In addition, the processing of progastrin is known to be altered in situations of increased gastrin secretion, such as in patients with gastrinomas and in patients or animals with low gastric acidity, often resulting in higher proportions of intermediates (4, 18, 31, 35).
In light of these observations, the determination of the pharmacokinetic properties and biological role of gastrin precursors is of some importance. Studies on the kinetics and biological activity of gastrin-17-Gly have been possible because it can be chemically synthesized (7, 26). However, experiments with progastrin have been very limited, because chemical synthesis of the progastrin polypeptide is not realistic; so the only studies with progastrin have been in transgenic mice overexpressing progastrin (38). It is likely that gastrin-17-Gly and progastrin will have distinct biological activities mediated by separate receptors.
We have developed a method for the purification of progastrin after expression in Escherichia coli (2) to determine its biological activity and to characterize the receptors involved. Here, we present data on the stability of recombinant progastrin in plasma and its pharmacokinetic characteristics in the conscious animal. Because chain length and amino acid derivitization are determinants of peptide metabolism, we have also examined gastrin-17-Gly and a COOH-terminal fragment of progastrin, Tyr70-progastrin-(71-80).
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Peptides
Gastrin-17-Gly and Tyr70-progastrin-(71-80) were custom synthesized by Auspep (Melbourne, Australia). Recombinant human progastrin-(6-80) was synthesized as a glutathione-S-transferase fusion protein in E. coli strain NM522. Briefly, the fusion protein was isolated from the bacterial lysate with glutathione-agarose and cleaved with thrombin. Progastrin-(6-80) was then purified by reverse-phase HPLC and characterized by radioimmunoassy, amino acid sequencing, and mass spectrometry (2).Subjects and Animals
Fresh human plasma was obtained from healthy adult volunteers. Nonpregnant Merino-Corriedale ewes or plasma from these animals was used for the animal studies.Experimental Design
Human plasma: in vitro stability.
Approximately 45 ml of peripheral venous blood were taken from the
brachial vein and collected into lithium-heparin tubes on ice. The
blood was centrifuged at 1,860 g for 15 min at 4°C and the
separated plasma stored at 20°C for a maximum of 1 wk before use.
Progastrin-(6-80) [0.5 ml, or 4 pmol/ml, in
buffer A (0.02 mol/l veronal, 0.1% BSA, 0.005% sodium
azide, pH 8.2)] was added to 19.5 ml of room temperature plasma from
each volunteer (n = 2) to give a final theoretical
concentration of 100 fmol/ml. The plasma was mixed and immediately
incubated at 37 or 4°C. One-milliliter samples were taken at
20, 0, and 30 min and 1, 2, 4, 8, 16, and 24 h and immediately ethanol
treated (2 ml of 100% ethanol) to precipitate large proteins. After
centrifugation, the supernatant was subsequently radioimmunoassayed
with antiserum 1137 (directed to the COOH terminus of progastrin) as
described in COOH-terminal progastrin. For sizing
chromatography, combined plasma (2 ml) from two volunteers was spiked
with a 200 pmol/ml stock of progastrin-(6-80) to give
a final theoretical concentration of 10 pmol/ml, mixed and incubated at
37°C. Samples were taken at 0, 2, and 24 h, snap frozen in
liquid nitrogen, and stored at
20°C.
Ovine plasma: in vitro stability.
Approximately 100 ml of peripheral venous blood were taken from the
jugular vein and collected into lithium-heparin tubes on ice. The blood
was centrifuged, separated, and stored as for the human blood.
Progastrin-(6-80) (1 ml, or 4 pmol/ml, in veronal buffer) was added to 39 ml of room temperature plasma from each sheep
(n = 3) to give a final concentration of 100 fmol/ml.
Similarly, 0.5 ml of stock was added to 9.5 ml of buffer A
to give a final concentration of 200 fmol/ml (n = 2).
The solutions were immediately incubated at 37 or 4°C. One-milliliter
samples of plasma were taken at 20, 0, and 30 min and 1, 2, 4, 8, 16, and 24 h and ethanol treated as for human plasma for assay
with antiserum 1137. Buffer samples were snap frozen in liquid nitrogen.
In vivo stability.
Sheep were fasted for 18-24 h before the experiment and weighed.
Local anesthetic (2 ml of 1% xylocaine) was administered to the skin
surrounding the jugular veins. A polyvinyl cannula (0.76 mm ID, 1.6 mm
OD) was passed through a needle inserted upward into the left jugular
vein, secured, and kept patent with 1,000 U/ml heparin sodium (sample
line). Likewise, the infusion line was prepared by cannulating the
right jugular vein downward. The next day, the left cannula was cleared
of heparin before blood samples were taken at 20 and 5 min before 2 ml
of recombinant progastrin-(6-80) (~250 nM in 0.1%
wt/vol BSA in physiological saline) were injected into the right
cannula. The peptide was flushed in with 10 ml of 50 U/ml heparin
sodium. This procedure gave an estimated final concentration of 200 pmol/l in the sheep circulation. Samples were taken from the left
cannula at 1, 2, 3, 4, 5, 7, 10, 15, 20, 30, 60, and 120 min after
injection. The line was kept patent with a solution of heparin (50 U/ml) in saline and cleared before and after each time point. Blood was
collected into lithium-heparin tubes and placed on ice before
centrifugation (as for human plasma). Plasma was stored at 20°C
until assay. This procedure was repeated on separate days with the
peptides human Tyr70-progastrin-(71-80)
or human gastrin-17-Gly to give estimated final concentrations of 500 and 200 pmol/l, respectively, in the sheep circulation. At least
24 h separated each experiment.
Laboratory Analysis
Chromatography. IN VITRO SAMPLES.
Each time point of human plasma from the superspiked in vitro experiments was applied separately to a Sephadex G50 (superfine) column (10 × 1,200 mm; Pharmacia, Uppsala, Sweden), which was eluted at 4°C with 0.02 M veronal buffer containing 0.05% BSA and 0.005% sodium azide, pH 8.2. The flow rate was 7.4 ± 0.1 ml/h (mean ± SD), and 10-min fractions were collected. Blue dextran (Pharmacia) and Na-125I (ICN, Sydney, Australia) were used to determine the void and the total volumes, respectively. The columns were calibrated with progastrin-(6-80), Tyr70-progastrin-(71-80), and 125I-labeled gastrin-17 amide. Column fractions were assayed with antisera directed to the COOH- and NH2-terminal parts of progastrin. IN VIVO SAMPLES. Plasma (2.5 ml) was taken from each progastrin-(6-80) in vivo experiment at +10 min (n = 4) and pooled. Progastrin and derived peptides were concentrated using a C18 Sep-Pak (Waters Associates, Melbourne, Australia) and then applied to a Sephadex G50 column (as described). The flow rate was 4.6 ± 0.1 ml/h, and 10-min fractions were collected. The void volume, total volume, and column calibrations were performed as described. Column fractions were assayed for COOH- and NH2-terminal progastrin and total gastrin.Radioimmunoassay. The four region-specific antisera (Fig. 1) that were used recognized 1) gastrin-Gly (no. 7270), 2) COOH-terminal progastrin (no. 1137), 3) NH2-terminal progastrin (no. 88235), and 4) all molecular forms of gastrin regardless of the degree of processing (total gastrin; no. 8017).
Gastrin-Gly. In vivo plasma samples were measured with antiserum 7270 by use of a previously reported radioimmunoassay (7). This antiserum detects human but not ovine glycine-extended gastrin and does not cross-react with amidated gastrin or CCK-Gly (Fig. 1) (14). The specific activity of [125I]gastrin-17-Gly was 3.0 ± 0.4 µCi/pmol (n = 2), the ID50 was 1.8 ± 0.4 (n = 4) fmol/ml, and the intra- and interassay coefficients of variation were 7.3 and 7.2%, respectively.
COOH-terminal progastrin. Antiserum 1137, which was raised against the COOH-terminal decapeptide of human progastrin (6), has a high specificity for intact progastrin and does not detect COOH-terminal-flanking peptides with fewer than eight residues. Antiserum 1137 (diluted to 1:200,000) was used to measure progastrin in Sephadex G50 column fractions and in vitro-spiked buffer samples against a buffer A standard curve. Tyr70-progastrin-(71-80) (Auspep; Melbourne, Australia) was used for the standard curve and [125I]Tyr70-progastrin-(71-80), which was iodinated using a modified chloramine-T method, for the tracer. The specific activity of the labeled peptide was 3.0 ± 0.7 µCi/pmol (n = 2), the ID50 was 2.7 ± 0.5 (n = 4) fmol/ml, and the intra- and interassay coefficients of variation were 3.4 and 8.4%, respectively.
Plasma samples required ethanol extraction before radioimmunoassay. Two volumes of 100% ethanol were added to the plasma, which was centrifuged at 1,860 g for 15 min at 4°C. Aliquots (1 ml) of supernatant were dispensed into two tubes and blown dry. The average recovery of progastrin-(6-80) from this procedure was 64.2 ± 3.1% (mean ± SE). The tubes containing the extracted plasma were assayed against a species-specific extracted plasma standard curve constructed in tubes containing the equivalent volume of ethanol-extracted, charcoal-stripped plasma. The calculated ID50 for this assay was 2.8 ± 0.6 fmol/tube (n = 4).NH2-terminal progastrin. Antiserum 88235, which was raised against human progastrin-(20-33), is specific for the sequence 20-33 of human progastrin. The antiserum detects the pentadecapeptide 20-33 and progastrin-(20-72) amide equally well. Progastrin fragments extended NH2 terminally to 20-33 have ~50% cross reactivity, whereas cross reactivity to progastrin fragments without amino acid 20 is 10% and without residues 20 and 21 is 0.1% (30). Antiserum 88235 (diluted to 1:500,000) was used to measure progastrin in Sephadex G50 column fractions against a buffer A standard curve constructed with Tyr34-progastrin-(20-34) (kindly supplied by Jens Rehfeld) as standard and [125I]Tyr34-progastrin-(20-34) as tracer.
Total gastrin.
Antiserum 8017 detects the NH2-terminal portion of
gastrin-17, which is exposed after tryptic digestion (Fig. 1). Hence,
all unprocessed, partially processed, and mature forms of gastrin (total gastrin) are measured with this procedure. Tryptic digestion of
the chromatographic fractions was performed using previously optimized
conditions for temperature, buffer, incubation time, and trypsin
concentrations (6). Samples were incubated with equal
volumes of trypsin (50 µg/ml; Calbiochem, San Diego, CA) in 0.02 mol/l veronal buffer (containing 0.1% charcoal-stripped human plasma
and 0.005% sodium azide, pH 8.2) and incubated at 37°C for 2 h.
Digestion was terminated by boiling for 2 min and then cooling on ice
for 5 min. Samples were stored at 20°C until assay. The samples
were then radioimmunoassayed using antiserum 8017 (diluted 1:2 × 106) against a gastrin-17 amide standard curve, with
[125I]gastrin-17 amide as the label (6).
Calculations
The pharmacokinetic analysis of Tyr70-progastrin-(71-80) was performed according to a single-compartment, open model (40). This model is described by the equation
![]() |
![]() |
![]() |
![]() |
The MCR was calculated from the injected dose (D) and the area
under the curve (AUC) by the equation
![]() |
![]() |
![]() |
![]() |
The data were fitted to the equations for the one- and two-compartment models by nonlinear regression with the program Sigmastat (Jandel Scientific, San Rafael, CA). All results are expressed as means ± SE. Statistical analysis was performed by one-way repeated measures analysis of variance followed by a Tukey's test for pairwise multiple comparisons. P values < 0.05 were considered significant.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
In vitro Pharmacokinetics
Recombinant human progastrin-(6-80) appeared to be very stable in human (Fig. 2A) or ovine (Fig. 2B) plasma, with no significant fall in immunoreactivity measured with the COOH-terminal-directed antiserum 1137 after 24 h at either 4 or 37°C. Similarly, recombinant progastrin was stable in ovine blood, with 87 ± 1% (n = 3) of the initial concentration remaining after incubation at 37°C for 24 h. As expected, there was no measurable loss of immunoreactivity when progastrin was incubated in buffer at either 4 or 37°C for 24 h (data not shown).
|
To confirm that no significant degradation of progastrin had occurred,
the progastrin-spiked plasmas after incubation for 0, 2, or 24 h
at 37°C were applied independently to a sizing column. The elution
positions of progastrin-derived peptides were then determined with
antisera directed against the COOH terminus or NH2 terminus
of progastrin (Fig. 3). In the time
0 sample, all of the immunoreactivity co-eluted with intact
progastrin when measured with the COOH-terminal antiserum (Fig.
3A). In addition, a minor peak (termed DP2; 16.9% total
peak area), reactive only to the NH2-terminal antiserum
88235, eluted as a broad peak with an elution fraction
(Kav) of 0.40 (Fig. 3B). In
the 2-h sample, the profile was unchanged with either the COOH-terminal
antiserum (Fig. 3C) or the NH2-terminal
antiserum (Fig. 3D; peak area DP2 18.9% total), but in the
24-h sample, the proportion of the NH2-terminal-reactive peak increased (Fig. 3F; peak area DP2 27.1% total). A new
peak also appeared (termed DP1; Kav 0.31), which
was detectable only with antiserum 1137 (Fig. 3E). The peak
area of progastrin-(6-80) at 24 h, measured by
antiserum 1137, decreased by ~10% compared with the time
0 sample, with a corresponding increase in the
COOH-terminal-reactive fragment (DP1). The NH2-terminal
antiserum measured similar changes, with an ~10% fall in intact
progastrin and a reciprocal increase in the
NH2-terminal-reactive fragment (DP2). On the basis of the log-linear relationship between the elution positions of
progastrin-(6-80), gastrin amide,
Tyr70-progastrin-(71-80), and
Kav, the molecular masses of the
COOH-terminal fragment DP1 (Kav 0.31) and the
NH2-terminal fragment DP2 (Kav 0.40)
were calculated to be 5,700 and 4,250 Da, respectively.
|
In vivo Pharmacokinetics
To determine MCR, apparent Vd, and disappearance half-lives, samples of human progastrin, gastrin-17-Gly, and Tyr70-progastrin-(71-80) were injected on separate occasions into four adult ewes. Figure 4 displays the circulating concentrations of the three peptides at various times after injection.
|
Gastrin-Gly.
The basal gastrin-Gly concentration increased from 8 ± 3 pmol/l
to a maximum of 142 ± 23 pmol/l after the injection. A biphasic disappearance of the peptide from the circulation was observed for each
of the four sheep (Fig. 5A).
The disappearance half-life in the primary or -phase was 2.2 ± 0.6 min, and in the secondary or
-phase was 13 ± 1 min. The
fraction of elimination in the
-phase was 0.83, indicating that the
major part of the elimination occurred during this phase. The MCR and
Vd were 7.4 ± 1.1 ml · kg
1 · min
1 and
142 ± 35 ml/kg, respectively (Table
1).
|
|
Progastrin-(6-80).
The peak level of progastrin immunoreactivity measured with antiserum
1137 was 174 ± 13 pmol/l after injection of 400 pmol of
progastrin-(6-80). As for gastrin-Gly, a biphasic
disappearance of the peptide from the circulation was observed (Fig.
5B). The half-life in the -phase was 5.1 ± 1.1 min
and in the
-phase 42 ± 11 min. The major part of the
elimination (~80%) occurred during the
-phase. The MCR and
Vd were 2.4 ± 0.2 ml · kg
1 · min
1 and
146 ± 40 ml/kg, respectively (Table 1).
|
Tyr70-progastrin-(71-80).
A monophasic disappearance of the peptide from the circulation was
observed (Fig. 5C), in contrast to
progastrin-(6-80) and gastrin-17-Gly, which had
biphasic disappearance profiles. The disappearance half-life of this
11-amino acid peptide was 0.9 ± 0.1 min, and the MCR and
Vd were 187 ± 39 ml · kg1 · min
1 and
235 ± 38 ml/kg, respectively (Table 1).
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The nonamidated forms of a number of gastrointestinal-regulatory peptides, including gastrin, secretin, vasoactive intestinal peptide, and gastrin-releasing peptide, are known to be biologically active (29). Gastrin is of particular interest, because the amidated and nonamidated forms have distinct actions that are mediated by separate receptors. Gastrin amide is a hormonal stimulant of gastric acidity that acts via the gastrin/CCK-B receptor, whereas the nonamidated forms have growth-promoting effects on the large bowel (3, 20). The mode of action (autocrine, paracrine, or endocrine) and the nature of the receptors for the nonamidated forms of gastrin have not been determined (3, 10, 20).
We have determined the in vitro and in vivo pharmacokinetics of recombinant progastrin-(6-80) and compared this with another nonamidated form, glycine-extended gastrin-17, and a derivative of the COOH-terminal-flanking peptide (CTFP) of progastrin, Tyr70-progastrin-(71-80). Until the present study, the largest form of nonamidated gastrin for which pharmacokinetics had been determined was glycine-extended gastrin-17 (7, 27), and no studies on progastrin-derived peptides with an unmodified COOH terminus had been reported. The sheep is a suitable model for determining the metabolism of progastrin and progastrin-derived peptides, as multiple blood sampling is practicable and the clearance and processing of glycine-extended and amidated gastrins are comparable among dog, human, and sheep (7, 26, 27). The control systems regulating gastrin release, such as gastric acidity, gastrin-releasing peptide, somatostatin, and acetylcholine are also similar between man and sheep (22, 41, 42).
The removal of progastrin-(6-80) from the circulation followed biphasic exponential kinetics with primary and secondary half-lives of 5.1 and 42 min, respectively. The long disappearance half-life was not the result of the generation of long-lived metabolites, since sizing chromatography of a +10-min blood sample revealed only one other peak comprising <15% of total immunoreactivity. Similarly, progastrin-(6-80) was stable in vitro, with no measurable loss in immunoreactivity after 24-h incubation in plasma or blood at 37°C. In contrast, the CTFP of progastrin, Tyr70-progastrin-(71-80), was rapidly cleared from the circulation, with a disappearance half-life of 0.9 min. These findings are consistent with the proposal that the disappearance half-life of a class of peptide is related to the number of amino acids it contains (12, 15, 37). Accordingly, glycine-extended gastrin-17 had disappearance half-lives (primary, 2.2 ± 0.6 min; secondary, 13 ± 1 min) intermediate between the two progastrin peptides. Until the present study, gastrin-52 amide was the largest gastrin peptide with known pharmacokinetics (24, 25). The disappearance half-lives of gastrin-52 amide (initial 4.9 ± 0.7, secondary 50 ± 4 min) were similar to those of progastrin-(6-80), suggesting that the determining element is peptide length rather than the COOH-terminal sequence. The sites of elimination for progastrin remain to be determined, but the present in vitro studies indicate that circulating enzymes are not responsible. The data from gastrin-52 amide metabolism in pigs indicate that the kidney and head would be the most likely organs to be involved (24).
Comparison of the pharmacokinetics of intact progastrin and its CTFP is of interest, as both are present in the antrum. In the normal human antrum, up to 15% of progastrin immunoreactivity is intact progastrin, as assessed either by specific antisera or by the total gastrin assay (which quantitates a processing-independent fragment of progastrin) (28, 29). The proportion of nonamidated gastrins, including progastrin, is substantially elevated in hypersecretory antral G cells and in gastrinomas and colorectal cancers (31). By use of the total gastrin assay, this increased ratio of nonamidated gastrins is also seen in the plasma of these patients (4, 6, 18). However, there are no reports on the proportions of intact progastrin vs. the CTFP in the circulation, because the total gastrin assays would not detect the smaller form and current CTFP-specific antisera are not suitable for measurement of the low concentrations present in normal serum. The slower clearance of the intact progastrin in the present study would suggest that this form should predominate. However, formal studies on the relative secretory rates are required. The Vd and MCR for the CTFP were much higher than for the other two peptides, suggesting that the small peptide is being distributed or sequestered to extravascular sites. A similar finding was reported for gastrin-6 amide, again suggesting that size, rather than the nature of the COOH terminus, was the more important determinant (24).
Gel chromatography of progastrin-(6-80) from both the in vivo and in vitro experiments revealed that the majority of the immunoreactivity eluted with intact progastrin-(6-80). Two degradation products were detected, namely a COOH-terminal peak with a Kav of 0.30 (DP1) and an NH2-terminal peak with a Kav of 0.40 (DP2). The small amounts of DP1 and DP2 precluded complete purification and subsequent determination of amino acid sequence, and the multiple potential processing sites (10, 29, 36) mean that a structure based on predicted processing can be of only limited value. Nevertheless, on the basis of the elution positions, antibody specificities, and the assumption that progastrin is cleaved at dibasic residues, the most probable candidate for DP1 is progastrin-(36-80). In agreement with this proposal is the finding that progastrin-(1-35) and progastrin-(6-35) were found as processing products in human gastrinoma extracts (16, 31). It is not clear to what extent infused gastrins are processed at dibasic residues in the circulation. A small proportion of infused gastrin-52 amide is cleaved at Arg36Arg37 to produce gastrin-34 amide (25), but gastrin-17 amide is not increased after gastrin-34 amide infusion (37). The nature of the NH2-terminal fragment DP2 remains to be determined, but as the NH2-terminal antiserum requires amino acids 20 and 21 to be immunoreactive, possibilities include progastrin-(6-46), progastrin-(20-54), or progastrin-(20-53). The injected progastrin-(6-80) was not processed into gastrin-Gly or -amide in vivo, since no immunoreactivity was detected when the nontrypsinized plasma samples containing the progastrin were assayed with antiserum directed against the NH2 terminus of gastrin-17 (antiserum 8017, data not shown). This observation was confirmed when the sample was chromatographed and assayed for total gastrin. No peaks additional to intact progastrin were detected.
Progastrin-(6-80) and
gastrin-(1-17)-Gly both exhibited biphasic
disappearance half-lives. The initial phase (-phase) is thought to
represent the immediate removal of peptide from the circulation, and
the
-, or elimination, phase represents organ-specific metabolism
and removal (40). As discussed by Palnæs Hansen et al.
(25), the proportion of the peptide cleared in each phase can be determined by the fraction of elimination, F
and F
.
Because the F
s for progastrin and gastrin-Gly were ~0.8, the
t1/2
s for progastrin (42 ± 11 min) and
gastrin-Gly (13 ± 1 min) are the relevant disappearance
half-lives.
In conclusion, the present study shows that full-length progastrin is more stable in the circulation than glycine-extended gastrin-17. In contrast, the CTFP is rapidly metabolized. These results will form a basis for determining whether progastrin has a physiological role as a circulating hormone. However, the circulating forms of progastrin, the extent of postsecretory processing, the sequence required for biological activity, and the nature of the receptors involved all remain unclear. It will be important to address these questions in light of the reports that progastrin and its intermediates accelerate the development of colorectal cancer (3) and sustain acid secretion stimulated by gastrin amide (5).
![]() |
ACKNOWLEDGEMENTS |
---|
We thank Josephine Baker and Lisa Hogan for expert technical assistance. We are grateful to Prof. Jens Rehfeld (Rigshopitalet, Copenhagen, Denmark) for kindly donating antisera 8017, 7270, and 88235 and human progastrin-(20-33).
![]() |
FOOTNOTES |
---|
This work was supported by Grants 960258 (A. Shulkes), 114123 (A. Shulkes), and 980625 (G. Baldwin) from the National Health and Medical Research Council of Australia, and by the Austin Hospital Medical Research Foundation.
Address for reprint requests and other correspondence: A. Shulkes, Dept. of Surgery, Univ. of Melbourne, Austin, and Repatriation Medical Centre, Austin Campus, Studley Rd., Heidelberg, Victoria 3084, Australia (E-mail: aas{at}unimelb.edu.au).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
April 23, 2002;10.1152/ajpendo.00042.2002
Received 1 February 2002; accepted in final form 17 April 2002.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Aly, A,
Shulkes A,
and
Baldwin GS.
Short term infusion of glycine-extended gastrin17 stimulates proliferation and formation of aberrant crypt foci in rat colonic mucosa.
Int J Cancer
94:
307-313,
2001[ISI][Medline].
2.
Baldwin, GS,
Hollande F,
Yang Z,
Karelina Y,
Paterson A,
Strang R,
Fourmy D,
Neumann G,
and
Shulkes A.
Biologically active recombinant human progastrin6-80 contains a tightly bound calcium ion.
J Biol Chem
276:
7791-7796,
2001
3.
Baldwin, GS,
and
Shulkes A.
Gastrin, gastrin receptors and colorectal carcinoma.
Gut
42:
581-584,
1998
4.
Bardram, L.
Progastrin in serum from Zollinger-Ellison patients. An indicator of malignancy?
Gastroenterology
98:
1420-1426,
1990[ISI][Medline].
5.
Chen, D,
Zhao CM,
Dockray GJ,
Varro A,
Van Hoek A,
Sinclair NF,
Wang TC,
and
Koh TJ.
Glycine-extended gastrin synergizes with gastrin17 to stimulate acid secretion in gastrin-deficient mice.
Gastroenterology
119:
756-765,
2000[ISI][Medline].
6.
Ciccotosto, GD,
McLeish A,
Hardy KJ,
and
Shulkes A.
Expression, processing and secretion of gastrin in patients with colorectal cancer.
Gastroenterology
109:
1142-1153,
1995[ISI][Medline].
7.
Ciccotosto, GD,
and
Shulkes A.
Pharmacokinetics and organ specific metabolism of glycine-extended and amidated gastrin in sheep.
Am J Physiol Gastrointest Liver Physiol
263:
G802-G809,
1992
8.
Dickinson, CJ,
Marino L,
and
Yamada T.
Inhibition of the -amidation of gastrin: effects on gastric acid secretion.
Am J Physiol Gastrointest Liver Physiol
258:
G810-G814,
1990
9.
Dockray, GJ.
Gastrin and gastric epithelial physiology.
J Physiol
518:
315-324,
1999
10.
Dockray, GJ,
Varro A,
Dimaline R,
and
Wang T.
The gastrins: their production and biological activities.
Annu Rev Physiol
63:
119-139,
2001[ISI][Medline].
11.
Eipper, BA,
Stoffers DA,
and
Mains RE.
The biosynthesis of neuropeptides: peptide alpha-amidation.
Annu Rev Neurosci
15:
57-85,
1992[ISI][Medline].
12.
Eysselein, VE,
Maxwell W,
Reedy T,
Wunsch E,
and
Walsh JH.
Similar acid stimulatory potencies of synthetic human big and little gastrins in man.
J Clin Invest
73:
1284-1290,
1984[ISI][Medline].
13.
Hersey, S,
and
Sachs G.
Gastric acid secretion.
Physiol Rev
75:
155-189,
1995
14.
Hilsted, L.
Glycine extended gastrin precursors.
Regul Pept
36:
323-343,
1991[ISI][Medline].
15.
Hirst, BH,
Holland J,
Marr AP,
Parsons ME,
and
Sanders DJ.
Comparison of effect of peptide length and sulfation on acid secretory potency of gastrin in the cat in vivo and in vitro.
J Physiol
357:
441-452,
1984[Abstract].
16.
Huebner, VD,
Jiang RL,
Lee TD,
Legesse K,
Walsh JH,
Shively JE,
Chew P,
Azumi T,
and
Reeve JR.
Purification and structural characterisation of progastrin-derived peptides from a human gastrinoma.
J Biol Chem
266:
12223-12227,
1991
17.
Iwase, K,
Evers BM,
Hellmich MR,
Guo Y-S,
Higashide S,
Kim HJ,
and
Townsend CM, Jr.
Regulation of growth of human gastric cancer by gastrin and glycine-extended progastrin.
Gastroenterology
113:
782-790,
1997[ISI][Medline].
18.
Jensen, S,
Borch K,
Hilsted L,
and
Rehfeld JF.
Progastrin processing during antral G-cell hypersecretion in humans.
Gastroenterology
96:
1063-1070,
1989[ISI][Medline].
19.
Kochman, ML,
DelValle J,
Dickinson CJ,
and
Boland CR.
Post-translational processing of gastrin in neoplastic human colonic tissues.
Biochem Biophys Res Commun
189:
1165-1169,
1992[ISI][Medline].
20.
Koh, TJ,
and
Chen D.
Gastrin as a growth factor in the gastrointestinal tract.
Regul Pept
93:
37-44,
2000[ISI][Medline].
21.
Kopin, AS,
Lee YM,
McBride EW,
Miller LJ,
Lu M,
Lin HY,
Kolakowski LF,
and
Beinborn M.
Expression cloning and characterization of the canine parietal cell gastrin receptor.
Proc Natl Acad Sci USA
89:
3605-3609,
1992[Abstract].
22.
Lawton, DE,
Simcock DC,
Candy EJ,
and
Simpson HV.
Gastrin secretion by ovine antral mucosa in vitro.
Comp Biochem Physiol A Mol Integr Physiol
126:
233-243,
2000[ISI][Medline].
23.
Nemeth, J,
Taylor B,
Pauwels S,
Varro A,
and
Dockray GJ.
Identification of progastrin derived peptides in colorectal carcinoma extracts.
Gut
34:
90-95,
1993[Abstract].
24.
Palnæs Hansen, C,
Goetze JP,
Stadil F,
and
Rehfeld JF.
The metabolism of gastrin-52 and gastrin-6 in pigs.
Am J Physiol Gastrointest Liver Physiol
279:
G552-G560,
2000
25.
Palnæs Hansen, C,
Stadil F,
and
Rehfeld JF.
Metabolism and influence of gastrin-52 on gastric acid secretion in humans.
Am J Physiol Gastrointest Liver Physiol
269:
G600-G605,
1995
26.
Palnaes Hansen, C,
Stadil F,
and
Rehfeld JF.
Metabolism and influence of glycine-extended gastrin on gastric acid secretion in man.
Digestion
57:
22-29,
1996[Medline].
27.
Palnæs Hansen, C,
Stadil F,
Yucin L,
and
Rehfeld JF.
Pharmacokinetics and organ metabolism of carboxyamidated and glycine-extended gastrins in pigs.
Am J Physiol Gastrointest Liver Physiol
271:
G156-G163,
1996
28.
Pauwels, S,
Desmond H,
Dimaline R,
and
Dockray GJ.
Identification of progastrin in gastrinomas, antrum, and duodenum by a novel radioimmunoassay.
J Clin Invest
77:
376-381,
1986[ISI][Medline].
29.
Rehfeld, JF.
The new biology of gastrointestinal hormones.
Physiol Rev
78:
1087-1108,
1998
30.
Rehfeld, JF,
and
Johnsen AH.
Identification of gastrin component I as gastrin-71: the largest possible bioactive progastrin product.
Eur J Biochem
223:
765-773,
1994[Abstract].
31.
Rehfeld, JF,
and
van Solinge WW.
The tumour biology of gastrin and cholecystokinin.
Adv Cancer Res
63:
295-346,
1994[ISI][Medline].
32.
Siddheshwar, RK,
Gray JC,
and
Kelly SB.
Plasma levels of progastrin but not amidated gastrin or glycine extended gastrin are elevated in patients with colorectal carcinoma.
Gut
48:
47-52,
2001
33.
Smith, AM,
and
Watson SA.
Gastrin and colorectal cancer.
Aliment Pharmacol Ther
14:
1231-1247,
2000[ISI][Medline].
34.
Van Solinge, WW,
Nielsen FC,
Friis-Hansen L,
Falkmer UG,
and
Rehfeld JF.
Expression but incomplete maturation of progastrin in colorectal carcinomas.
Gastroenterology
104:
1099-107,
1993[ISI][Medline].
35.
Varro, A,
Nemeth J,
Bridson J,
Lonovics J,
and
Dockray GJ.
Modulation of posttranslational processing of gastrin precursor in dogs.
Am J Physiol Gastrointest Liver Physiol
258:
G904-G909,
1990
36.
Walsh, JH.
Gastrin.
In: Gut Peptides: Biochemistry and Physiology, edited by Walsh JH,
and Dockray GJ. New York: Raven, 1994.
37.
Walsh, JH,
Isenberg JI,
Ansfield J,
and
Maxwell W.
Clearance of acid-stimulating actions of human big and little gastrins in duodenal ulcer subjects.
J Clin Invest
57:
1125-1131,
1976[ISI][Medline].
38.
Wang, TC,
Koh TJ,
Varro A,
Cahill RJ,
Dangler CA,
Fox JG,
and
Dockray GJ.
Processing and proliferative effects of human progastrin in transgenic mice.
J Clin Invest
98:
1918-1929,
1996
39.
Wank, SA.
Cholecystokinin receptors.
Am J Physiol Gastrointest Liver Physiol
269:
G628-G646,
1995
40.
Wartuk, J.
Clinical Pharmacokinetics: A Modern Approach to Individualized Drug Therapy. New York: Praeger, 1983.
41.
Westbrook, SL,
McDowell GH,
Hardy KJ,
and
Shulkes A.
Active immunization against somatostatin alters the regulation of gastrin in response to gastric acid secretagogues.
Am J Physiol Gastrointest Liver Physiol
274:
G751-G756,
1998
42.
Zavros, Y,
Fleming WR,
and
Shulkes A.
Concurrent elevation of fundic somatostatin prevents gastrin stimulation by GRP.
Am J Physiol Gastrointest Liver Physiol
276:
G21-G27,
1999